These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 9195286)

  • 1. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.
    Fox SB; Harris AL
    Invest New Drugs; 1997; 15(1):15-28. PubMed ID: 9195286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.
    Rüegg C; Meuwly JY; Driscoll R; Werffeli P; Zaman K; Stupp R
    Curr Mol Med; 2003 Dec; 3(8):673-91. PubMed ID: 14682490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.
    Gradishar WJ
    Invest New Drugs; 1997; 15(1):49-59. PubMed ID: 9195289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of angiogenesis in cancers.
    Pang RW; Poon RT
    Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of angiogenesis inhibitors for cancer therapy.
    Eckhardt SG; Pluda JM
    Invest New Drugs; 1997; 15(1):1-3. PubMed ID: 9195284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase inhibitors.
    Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
    Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical evaluation of angiogenesis inhibitors.
    O'Reilly MS
    Invest New Drugs; 1997; 15(1):5-13. PubMed ID: 9195285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing Tumor Angiogenesis in Histological Samples.
    Pang JM; Jene N; Fox SB
    Methods Mol Biol; 2016; 1430():3-33. PubMed ID: 27172943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis.
    Drevs J; Schneider V
    J Intern Med; 2006 Dec; 260(6):517-29. PubMed ID: 17116002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical biomarkers of angiogenesis inhibition.
    Brown AP; Citrin DE; Camphausen KA
    Cancer Metastasis Rev; 2008 Sep; 27(3):415-34. PubMed ID: 18414993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis.
    Christopoulos A; Ahn SM; Klein JD; Kim S
    Head Neck; 2011 Aug; 33(8):1220-9. PubMed ID: 21755565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising new treatments for neovascular age-related macular degeneration.
    Michels S; Schmidt-Erfurth U; Rosenfeld PJ
    Expert Opin Investig Drugs; 2006 Jul; 15(7):779-93. PubMed ID: 16787141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to anti-angiogenesis: an ever changing feature.
    Bertolini F
    Breast; 2011 Oct; 20 Suppl 3():S61-2. PubMed ID: 22015295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibition of tumor angiogenesis as a cancer treatment].
    Verheul HM; Bom JB; Hoekman K; Pinedo HM
    Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1549-55. PubMed ID: 10443279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Angiogenesis in Cancer Treatments: Where do we Stand?
    Petrovic N
    J Pharm Pharm Sci; 2016; 19(2):226-38. PubMed ID: 27518172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs.
    Fox SB; Gasparini G; Harris AL
    Lancet Oncol; 2001 May; 2(5):278-89. PubMed ID: 11905783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism and its regulation of tumor-induced angiogenesis.
    Gupta MK; Qin RY
    World J Gastroenterol; 2003 Jun; 9(6):1144-55. PubMed ID: 12800214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.
    Nienhüser H; Schmidt T
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.